Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2954628 | 0.86 | MEN1 (0.31) | RAB9A | |
| SCHEMBL24439824 | 0.82 | KDM4E (0.32) | KDM4EALDH1A1 | |
| SCHEMBL1680162 | 0.76 | — | — | |
| SCHEMBL2546921 | 0.69 | RIPK2 (0.38) | RIPK2LCKKDRTGFBR1KLK5 | |
| SCHEMBL22367276 | 0.67 | ALDH1A1 (0.42) | RPS6KA3KDM4EALDH1A1POLB | |
| SCHEMBL9869560 | 0.66 | RIPK2 (0.38) | RIPK2LCKKDRTGFBR1RPS6KA3 | |
| SCHEMBL23256252 | 0.66 | NPC1 (0.37) | RAB9A | |
| Hydrochloric Acid SCHEMBL28692305 | 0.65 | RIPK2 (0.37) | RIPK2LCKKDRTGFBR1RPS6KA3 | |
| SCHEMBL25241414 | 0.64 | GABRP (0.39) | KDM4EALDH1A1 | |
| SCHEMBL30900479 | 0.64 | SIRT1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809344-B2 | Compounds, compositions, and methods for control of hepatitis C viral infections | APATH, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| WO-2010096115-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | APATH, LLC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262397-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR CONTROL OF HEPATITIS C VIRAL INFECTIONS | HAVCR2, FABP1, HCCS | RIPK2 2913/4885LCK 2969/4885KDR 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.